HALOZYME THERAPEUTICS, INC.
HALOZYME THERAPEUTICS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on October 31, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.
HALOZYME THERAPEUTICS, INC. generates cash from operations, so a burn-based runway figure does not apply.
Across 32 concluded trials, 91% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 31, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| March 15, 2028 | 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism | Trial Milestone | Phase 3 |
Track HALO alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open HALO in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.